Business
Clinical Trial Initiated Of Wholly-Owned Candidate
Clinical Trial Initiated Of Wholly-Owned Candidate.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \n \n RNS Number : 7788E\n PureTech Health PLC\n 03 March 2020\n \n \n \n \n 3 March 2020\n \n \n PureTech Health plc\n \n \n \n \n \n PureTech Announces First Participant Dosed in Clinical Trial of Wholly-Owned Lymphoedema Candidate LYT-100 \n \n \n \n \n \n Multiple ascending dose and food effect study will be a follow-up to a previously conducted single ascending dose clinical trial of LYT-100\n \n \n \n \n \n Proof-of-concept study in patients with breast cancer-related lymphoedema also expected to begin this year\n \n \n \n \n \n \n \n PureTech Health plc\n \n \n (LSE: PRTC) (\"PureTech,\" or the \"Company\"), a clinical stage biotherapeutics company dedicated to discovering, developing and commercialising highly differentiated medicines for devastating diseases, today announced that the first participant has been dosed in a clinical study of LYT-100, PureTech's wholly-owned product candidate for the potential treatment of lymphoedema and other fibrotic conditions. There are currently no FDA-approved drugs to treat lymphoedema, which is a painful, progressive, and chronic condition that affects approximately one million individuals in the US alone, including about 500,000 breast cancer survivors. \n \n \n \n \n \n The Phase 1, multiple ascending dose and food effect study is designed to evaluate the safety, tolerability and pharmacokinetic (PK) profile of LYT-100 in healthy participants. This is a follow-up to the single ascending dose clinical trial of LYT-100 in healthy individuals that was conducted by Auspex. Results from the multiple ascending dose study are expected this year and will enable the initiation of a proof-of-concept study in people with breast cancer-related, upper limb secondary lymphoedema later in 2020. \n \n \n \n \n \n \"Lymphatic diseases cause significant disability and pain, yet there are few meaningful treatment options, most of which involve compression and physical therapy to control swelling,\" said Babak Mehrara, MD,\n chief, plastic and reconstructive surgical service, the Peter G. Cordeiro endowed chair in plastic and reconstructive surgery at Memorial Sloan Kettering Cancer Center and an advisor to PureTech. \"LYT-100 is designed to address the underlying cause of lymphoedema by reducing fibrosis and inflammation and restoring lymphatic function,...